DocMorris AG
SIX:DOCM

Watchlist Manager
DocMorris AG Logo
DocMorris AG
SIX:DOCM
Watchlist
Price: 5.95 CHF 1.88% Market Closed
Market Cap: 304.2m CHF

DocMorris AG
Investor Relations

DocMorris Ltd. engages in the operation of an e-commerce pharmacy and the wholesale of medical and pharmaceutical products. The company is headquartered in Frauenfeld, Thurgau and currently employs 2,283 full-time employees. The company went IPO on 2017-07-06. The firm focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The firm's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The firm operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.

Show more
Loading
DOCM
Swiss Market Index
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2025
Call Date
Aug 19, 2025
AI Summary
Q2 2025

Strong Rx Growth: Prescription (Rx) revenues grew by 43.5% in the first half of 2025, with eRx revenues nearly doubling year-on-year in Q2.

Services Scaling Fast: TeleClinic revenues increased over 150% year-on-year and is expected to contribute around 10% of group gross profit in 2025; service revenues overall grew by more than 120%.

Non-Rx Steady: Non-Rx business delivered 4.4% steady, profitable growth despite the closure of a key pharmacy in Germany.

Margin Improvement: Gross margin improved by 70 basis points year-on-year and 130 bps compared to the second half of 2024 due to better pricing and higher-margin services.

EBITDA Guidance Reaffirmed: Full-year guidance for EBITDA remains minus CHF 35 million to minus CHF 55 million, with the final figure mainly dependent on marketing spend.

Solid Funding: Completed CHF 200 million capital increase with a 99% take-up rate, strengthening the balance sheet.

AI Innovation: Beta rollout of the DocMorris Health Companion agentic assistant launched, aiming for a seamless digital health experience.

Key Financials
Rx Revenue Growth
43.5%
eRx Revenue Growth
1.8x YoY
TeleClinic Revenue Growth
Over 150% YoY
Service Revenue Growth
Over 120% YoY
Non-Rx Revenue Growth
4.4% YoY
Revenue Growth
10.2%
Adjusted EBITDA
minus CHF 28.8 million
Reported EBITDA
minus CHF 27.1 million
Capital Increase
CHF 200 million, 99% take-up rate
App Downloads
1.2 million in H1 2025
Repeat Order Rate
78%
Cash at Hand
CHF 230 million as of mid-year
Earnings Call Recording
Other Earnings Calls
2025

Management

Mr. Walter Oberhansli
Founder & Chairman
No Bio Available
Mr. Walter Hess
CEO & Member of Executive Board
No Bio Available
Mr. Daniel Wüest
CFO & Member of Executive Board
No Bio Available
Mr. David Maso
Head of Europe & Member of Executive Board
No Bio Available
Mr. Kaspar Niklaus
COO & Member of Executive Board
No Bio Available
Mr. Pablo Ros
CTO & Member of Executive Board
No Bio Available
Dr. Daniel Grigat
Group Head of Investor Relations & Sustainability
No Bio Available
Torben Bonnke
Director of Communications
No Bio Available

Contacts

Address
THURGAU
Frauenfeld
Walzmuehlestrasse 49
Contacts